TL;DR
This study investigates how well the immune systems of HIV-positive individuals on antiretroviral therapy (ART) recover their CD4 and CD8 T-cell counts and their ratio, comparing them to HIV-negative individuals. While starting ART with a higher CD4 count helps restore CD4 levels, persistently high CD8 counts prevent the CD4:CD8 ratio from reaching normal levels, suggesting ongoing immune challenges even with viral suppression.
What Problem Does This Paper Address?
Antiretroviral therapy (ART) has transformed HIV treatment, allowing individuals to achieve sustained virological suppression and live near-normal lifespans. A key indicator of immune health in HIV-positive individuals is the CD4 T-cell count, which is targeted by ART. Recent guidelines recommend offering ART earlier, even to individuals with high CD4 counts. This shift raises questions about the extent to which immune restoration (specifically CD4 and CD8 T-cell counts and their ratio) can be achieved in these individuals, and whether factors like age and initial CD4 count influence this recovery. The paper aims to understand the determinants of this immune restoration and whether it fully returns to levels seen in HIV-negative individuals, particularly focusing on the CD4:CD8 ratio, which is increasingly recognized as an important marker of immune health and prognosis.
Methods
The researchers used longitudinal data from a large international collaboration of HIV-positive individuals on ART (the Antiretroviral Therapy Cohort Collaboration - ART-CC). To establish reference values for immune cell counts and their ratios, they analyzed cross-sectional data from a cohort of HIV-negative individuals.
For the HIV-positive cohort, they employed linear mixed-effects models to analyze how CD4 and CD8 cell counts, and the CD4:CD8 ratio, changed over time after starting ART. These models accounted for various factors, including age, gender, transmission risk group, region of birth, and initial CD4 and viral load levels. They also performed sensitivity analyses to explore the impact of different definitions of virological suppression. The data was transformed (e.g., square root for CD4, log for CD8) to better fit the statistical models.
Datasets
- HIV-Negative Reference Population: 2309 individuals from Denmark and the Netherlands, used to establish median and quartile reference values for CD4 and CD8 cell counts and their ratio.
- HIV-Positive Study Population: Data from 60,997 HIV-positive individuals from the Antiretroviral Therapy Cohort Collaboration (ART-CC), an international collaboration of 21 cohort studies from Europe and North America. This dataset provided longitudinal measurements of CD4 and CD8 cell counts and viral load.
Key Insights and Ideas
- Early ART initiation matters for CD4 recovery: Starting ART with a higher CD4 cell count (≥500 cells/mm³) significantly increases the likelihood of reaching median CD4 cell counts comparable to HIV-negative individuals.
- CD8 counts remain elevated: Despite successful viral suppression with ART, CD8 cell counts tend to stabilize at levels higher than those seen in HIV-negative individuals. This persistence is a key factor limiting full immune restoration.
- The CD4:CD8 ratio struggles to normalize: Due to the persistently high CD8 cell counts, the CD4:CD8 ratio in HIV-positive individuals on ART rarely reaches the median levels observed in HIV-negative individuals, even with high initial CD4 counts.
- Age influences CD4 recovery, but differently in men and women: While middle-aged individuals generally showed better CD4 recovery, this effect was more pronounced in women.
- Baseline CD8 count is also a factor: Higher baseline CD8 cell counts are associated with higher CD8 cell counts at 8 years post-ART initiation, further contributing to the elevated levels.
Key Results
- CD4 Restoration: Median reference CD4 cell counts (around 800 cells/mm³) were achieved by men starting ART with CD4 counts ≥500 cells/mm³ within 8 years.
- CD8 Levels: CD8 cell counts converged towards median reference values within the first 2 years of ART but remained higher than reference levels long-term. Median 8-year CD8 counts were higher when ART was started with very low CD4 counts (<250 cells/mm³).
- CD4:CD8 Ratio: Median CD4:CD8 ratio trajectories did not reach median reference values, even when ART was initiated at 500 cells/mm³.
- Age Effects: Middle-aged individuals showed higher median CD4 cell counts at 8 years compared to younger and older individuals. Women aged 51-52 years showed the highest CD4 cell counts after 8 years of ART.
- Other Factors: Smokers had higher CD4 and CD8 cell counts after 8 years compared to non-smokers. Individuals infected via injecting drug use (IDU) had lower CD4 and CD4:CD8 ratio trajectories.
Limitations and Future Work
- Generalizability: The study excluded individuals with ART interruptions longer than 2 weeks or confirmed viral load >400 copies/mL. This means the results represent the maximum immune restoration capacity in well-adherent individuals and may not be generalizable to all patients.
- Pre-HIV Infection Data: The study lacked data on individuals' CD4 cell counts before HIV infection, making it difficult to compare current immune status to a true baseline.
- Sub-Saharan African Cohorts: While included, the interpretation of results from these cohorts might be limited due to potential differences in CD4 cell counts compared to Western populations.
- Clinical Endpoint Impact: The authors emphasize that the clinical significance of these "subnormal" immunological responses (specifically the persistent high CD8 counts and suboptimal CD4:CD8 ratio) on specific clinical endpoints requires further investigation. This is a crucial area for future research.
- Causality: While associations are identified, establishing direct causality for all observed differences (e.g., between smoking and immune cell counts) requires further study.
Summary updated